https://mtcancer.org/clinical-trials/alliance-a022102/
ALLIANCE A022102 - Montana Cancer Consortium
Randomized Phase III Trial of mFOLFIRINOX +/- Nivolumab vs. FOLFOX +/- Nivolumab for First-Line Treatment of Metastatic HER2-Negative Gastroesophageal
alliancemontanacancerconsortium